Global Pharma Companies Lining Up at Alteogen's Door – Why?
"By the 2030s, I envision Alteogen joining the ranks of companies with annual revenue in the trillions of won. We’ll see significant revenue from royalties and milestone payments tied to…
Hugel Successfully Concludes HA Filler workshop for French medical experts
Hugel Inc., a leading global medical aesthetics company, said on Wednesday it had recently launched H.E.L.F. Global Expert Workshop on hyaluronic acid dermal filler treatment for about 10 French medical…
Alteogen Signs USD 280 Million Licensing Agreement with Daiichi Sankyo
Alteogen is advancing in the development of the world’s first subcutaneous (SC) injection for antibody-drug conjugates (ADCs). On the 8th, Alteogen announced it signed an exclusive licensing agreement with Japanese…
Hugel Sees Record Q3 Revenue and Profit with Botulax Growth
For the first time since its founding, Hugel has exceeded 100 billion KRW in quarterly revenue and 50 billion KRW in quarterly operating profit. On the 6th, Hugel, a total…
Huons Acquires PanGen... “Expanding CDMO Services for Biopharmaceuticals”
Huons is set to expand its biopharmaceutical R&D and contract development and manufacturing organization (CDMO) services with its acquisition of PanGen, a specialized biopharmaceutical company. On the 5th, Huons (Co-CEOs…
Korean Dementia Association: “Leqembi's Side Effects Are Not Significant”
The Korean Dementia Association has addressed safety concerns related to the upcoming domestic release of the Alzheimer’s treatment Leqembi (ingredient: lecanemab), stating that the side effects are not significant enough…
Samsung Bioepis Projected to Reach 1.4 Trillion KRW in Sales
Samsung Bioepis has surpassed its total annual revenue from last year within the first three quarters of 2023. The company’s annual revenue is projected to exceed 1.4 trillion KRW (approx.…
Boryung Nearing 1 Trillion KRW in Annual Sales for the First Time
Boryung is getting closer to achieving 1 trillion KRW ($740 million) in annual sales for the first time, supported by strong third-quarter results. Its growth has been boosted by its…
Yuhan Corporation's Q3 Operating Profit Surges 690%
Yuhan Corporation’s third-quarter operating profit has skyrocketed, primarily due to license revenue from its out-licensed non-small cell lung cancer drug Leclaza. On the 28th, Yuhan reported that its standalone revenue…
Strong Performance Drives Samsung Biologics’ Price Target Upward
Following Samsung Biologics’ announcement of its third-quarter results, several securities firms have raised their target stock price for the company. This is largely due to the rapid ramp-up of operations…